Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

4-Traders Homepage  >  Equities  >  Deutsche Boerse AG  >  UCB SA    UNC   BE0003739530

UCB SA (UNC)

Real-time Quote. Real-time Tradegate - 05/26 09:20:50 am
60.12 EUR   +0.34%
05/22 UCB : and Amgen announce top-line phase 3 data from …
05/17 UCB : Transparency notification
05/04 Attention Deficit Hyperactivity Disorder ADHD Drug Sales Market 2..
SummaryQuotesChartsNewsAnalysisCalendarCompanyFinancialsConsensusRevisions 
News SummaryMost relevantAll newsSector newsTweets 
Latest news on UCB SA
05/22 UCB : and Amgen announce top-line phase 3 data from …
05/17 UCB : Transparency notification
05/04 Attention Deficit Hyperactivity Disorder ADHD Drug Sales Market 2017 - Shire,..
04/28 UCB : ex-dividend day for annual dividend
04/27 UCB : General Meeting of Shareholders
04/26 UCB : receives positive CHMP opinion for CIMZIA® (certolizumab pegol) dose &hell..
04/24 UCB FIRST THREE MONTHS INTERIM REPOR :  UCB with …
04/20 UCB : Findings from UCB S.A. Provides New Data on Epilepsy (Health care cost ass..
04/19UCB SA : quaterly earnings release
04/10 UCB : U.S. Patent and Trademark Office confirms validity of patent …
04/10 UCB : Acquisition of own shares
04/07 UCB : Acquisition of own shares
04/04 UCB : and Q-State Biosciences Form Research Collaboration …
04/03 AMGEN : Ucb and amgen report new data at endo 2017 examining the option of a sec..
04/01 UCB : AND AMGEN REPORT NEW DATA AT ENDO 2017 EXAMINING …
03/24 UCB : General Meeting on 27 April 27 2017
03/24 UCB : Convening notice to attend the general meeting of shareholders
03/23 UCB : U.S. Patent and Trademark Office confirms validity of patent …
03/17 UCB : Brussels - Transparency notifications
03/16 UCB : Transparency notifications
03/10 UCB : Acquisition of own shares
03/09 UCB : Researchers from UCB S.A. Report New Studies and Findings in the Area of E..
03/09 UCB : Transparency notification
03/09 SCHEDULES OF CONTROLLED SUBSTANCES : Placement of Brivaracetam Into Schedule V
03/08 UCB : Transparency notification
03/07 UCB : Transparency notification
03/06 UCB : New CIMZIA (certolizumab pegol) data in moderate-to-severe plaque psoriasi..
03/06 UCB : First CIMZIA Study of Its Kind Showed Minimal to No …
03/04 UCB : New CIMZIA® (certolizumab pegol) data in moderate-to-severe plaque &hellip..
03/02 UCB : Transparency Notifications
02/24 UCB : Transparency notifications BlackRock, Inc.
02/24 UCB : Transparency notification Wellington Management Group LLP
02/23 UCB FULL YEAR REPORT 2016 : UCB demonstrates continued top and …
02/16 UCB : Transparency notification
02/09 UCB : Transparency notifications
02/08 UCB : Transparency notifications
01/25 UCB : Transparency notifications
01/19 UCB : files BRIVIACT® (brivaracetam) CV in the U.S. as …
01/19 UCB : Final CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Primary Efficacy &h..
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency Notification
01/18 UCB : Transparency notification
01/18 UCB : Transparency notification
01/06 Lori Lyons-Williams Joins Dermira as Chief Commercial Officer
01/05 DERMIRA : Elects Emmanuel Caeymaex to Board of Directors
2016 DERMIRA,INC. (NASDAQ : DERM) Files An 8-K Departure of Directors or Certain Offi..
2016 UCB : Second CIMZIA (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy..
2016 UCB : Family Epilepsy Scholarship Program Announces 2016 Recipients
2016 UCB : Juno Biomedical Moving Forward with Regenerative Stroke Treatment
2016 UCB : The Lancet Publishes First Head-to-Head Study of Cimzia® (certolizumab peg..
2016 UCB : anti-epileptic drug VIMPAT® (lacosamide) receives positive opinion by EU C..
2016 UCB : Patent Issued for Method for Producing Protein (USPTO 9476081)
2016 UCB : continues its growth path
2016 UCB : Transparency notification
2016 UCB : Transparency notification
2016 UCB : Transparency notification
2016 UCB : CIMZIA® (certolizumab pegol) Phase 3 Trial Meets Co-primary Efficacy Endpo..
2016 UCB : Opens Solution Accelerator at Georgia Tech Technology Square
2016 UCB : and Amgen announce U.S. FDA acceptance of biologics licence application fo..
2016 UCB : Transparency notification
2016 UCB : receives positive EU CHMP opinion for CIMZIA® (certolizumab pegol) AutoCli..
2016 UCB : Results from phase 3 Frame study of romosozumab showed significant reducti..
2016 UCB : Transparency notification
2016 UCB : Transparency notifications
2016 DAIICHI SANKYO : Antiepileptic lacosamide filed for partial amendment of approva..
2016 UCB : Transparency notification
2016 UCB : Transparency notification
2016 UCB : U.S. District Court confirms validity of patent for UCB's Vimpat®
2016 AMPHASTAR PHARMACEUTICALS : Purchases International Medication Systems (UK) Limi..
2016 UCB : continues to deliver on its growth strategy
2016 AMGEN : UCB and Amgen submit biologics license application for Romosozumab to th..
2016 DAIICHI SANKYO : UCB and Daiichi Sankyo will jointly commercialize lacosamide in..
2016 UCB : and Daiichi Sankyo announce Japanese approval of lacosamide (brand name VI..
1  2  3  4  5  6Next
Advertisement
Financials (€)
Sales 2017 4 300 M
EBIT 2017 920 M
Net income 2017 594 M
Debt 2017 551 M
Yield 2017 2,00%
P/E ratio 2017 18,10
P/E ratio 2018 15,23
EV / Sales 2017 2,84x
EV / Sales 2018 2,58x
Capitalization 11 641 M
More Financials
Chart UCB SA
Duration : Period :
UCB SA Technical Analysis Chart | UNC | BE0003739530 | 4-Traders
Full-screen chart
Income Statement Evolution
More Financials
Consensus 
Mean consensus HOLD
Number of Analysts 16
Average target price 68,1 €
Spread / Average Target 14%
Consensus details
EPS Revisions
More Estimates Revisions
Managers
NameTitle
Jean-Christophe Tellier Chief Executive Officer & Executive Director
Gerhard N. Mayr Chairman
Detlef Thielgen Chief Financial Officer & Executive Vice President
Iris Löw-Friedrich Chief Medical Officer & Executive Vice President
Ismail Kola Chief Scientific Officer, EVP & Head-New Medicines
More about the company
Sector and Competitors
1st jan.Capitalization (M$)
UCB SA-2.38%13 032
JOHNSON & JOHNSON10.68%343 545
ROCHE HOLDING LTD.14.88%236 038
NOVARTIS AG6.68%212 104
PFIZER INC.-1.32%191 517
MERCK & CO., INC.10.48%177 895
More Results